Bi Chang, Bai Kailun, Zhang Xuekui
Department of Mathematics and Statistics, University of Victoria, 3800 Finnerty Road, Victoria, BC V8P 5C2, Canada.
Brief Bioinform. 2025 Jul 2;26(4). doi: 10.1093/bib/bbaf428.
Existing cell type annotation methods face significant hurdles: supervised approaches often fail to differentiate between novel cell types not present in reference data, while unsupervised techniques can suffer from cluster impurity and difficulties in robustly distinguishing multiple distinct unknown cell populations. This critical gap motivated the development of HiCat, a semi-supervised pipeline specifically designed to overcome these limitations. HiCat is a semi-supervised pipeline that integrates both approaches, leveraging reference (labeled) and query (unlabeled) genomic data to simultaneously enhance annotation accuracy for known cell types and improve the discovery and differentiation of novel ones. HiCat follows a structured pipeline: (1) removing batch effects and generate a low-dimensional embedding; (2) nonlinear dimensionality reduction for capturing key patterns; (3) unsupervised clustering for proposing novel cell type candidates; (4) merging multi-resolution features from previous steps into a condensed feature space; (5) training a classifier on reference data for supervised annotation; and (6) resolving inconsistencies between supervised predictions and unsupervised clusters to finalize annotations, particularly for unseen types. Performance was evaluated across 10 public genomic datasets and perform a case study on a molecular cell atlas of the human lung. HiCat demonstrated superior performance in both known cell type classification and novel cell type identification. In benchmark evaluations, HiCat consistently outperformed existing methods, critically excelling in identifying and distinguishing multiple novel cell types. HiCat presents a robust framework for scRNA-seq cell annotation, improving classification accuracy and novel type identification. In addition, it provides a scalable and transferable solution for biomedical research, directly addressing key challenges in automated cell annotation.
监督方法往往无法区分参考数据中不存在的新型细胞类型,而无监督技术可能会受到聚类不纯的影响,并且难以可靠地区分多个不同的未知细胞群体。这一关键差距促使了HiCat的开发,HiCat是一种专门设计用于克服这些限制的半监督流程。HiCat是一种半监督流程,它整合了两种方法,利用参考(标记)和查询(未标记)基因组数据,同时提高已知细胞类型的注释准确性,并改善新型细胞类型的发现和区分。HiCat遵循一个结构化流程:(1)消除批次效应并生成低维嵌入;(2)进行非线性降维以捕获关键模式;(3)进行无监督聚类以提出新型细胞类型候选;(4)将前几步的多分辨率特征合并到一个压缩特征空间;(5)在参考数据上训练分类器以进行监督注释;(6)解决监督预测和无监督聚类之间的不一致以最终确定注释,特别是对于未见类型。在10个公共基因组数据集上评估了性能,并对人类肺的分子细胞图谱进行了案例研究。HiCat在已知细胞类型分类和新型细胞类型识别方面均表现出卓越性能。在基准评估中,HiCat始终优于现有方法,在识别和区分多种新型细胞类型方面表现出色。HiCat为scRNA-seq细胞注释提供了一个强大的框架,提高了分类准确性和新型类型识别能力。此外,它为生物医学研究提供了一种可扩展且可转移的解决方案,直接解决了自动细胞注释中的关键挑战。